Guided Therapeutics (GTHP) Receivables - Net (2016 - 2025)
Historic Receivables - Net for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $6000.0.
- Guided Therapeutics' Receivables - Net rose 20000.0% to $6000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6000.0, marking a year-over-year increase of 20000.0%. This contributed to the annual value of $3000.0 for FY2024, which is 5968.83% down from last year.
- Latest data reveals that Guided Therapeutics reported Receivables - Net of $6000.0 as of Q3 2025, which was up 20000.0% from $8000.0 recorded in Q2 2025.
- Guided Therapeutics' 5-year Receivables - Net high stood at $165.0 million for Q1 2022, and its period low was $2000.0 during Q3 2024.
- In the last 5 years, Guided Therapeutics' Receivables - Net had a median value of $8000.0 in 2025 and averaged $16.7 million.
- Per our database at Business Quant, Guided Therapeutics' Receivables - Net surged by 13085238.1% in 2022 and then tumbled by 9996.65% in 2023.
- Quarter analysis of 5 years shows Guided Therapeutics' Receivables - Net stood at $171153.0 in 2021, then plummeted by 71.95% to $48000.0 in 2022, then crashed by 84.5% to $7442.0 in 2023, then plummeted by 59.69% to $3000.0 in 2024, then surged by 100.0% to $6000.0 in 2025.
- Its Receivables - Net stands at $6000.0 for Q3 2025, versus $8000.0 for Q2 2025 and $2000.0 for Q1 2025.